Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-7-27
pubmed:abstractText
Angelman syndrome (AS) is caused by reduced or absent expression of the maternally inherited ubiquitin protein ligase 3A gene (UBE3A), which maps to chromosome 15q11-q13. UBE3A is subject to genomic imprinting in neurons in most regions of the brain. Expression of UBE3A from the maternal chromosome is essential to prevent AS, because the paternally inherited gene is not expressed, probably mediated by antisense UBE3A RNA. We hypothesized that increasing methylation might reduce expression of the antisense UBE3A RNA, thereby increasing UBE3A expression from the paternal gene and ameliorating the clinical phenotype. We conducted a trial using two dietary supplements, betaine and folic acid to promote global levels of methylation and attempt to activate the paternally inherited UBE3A gene. We performed a number of investigations at regular intervals including general clinical and developmental evaluations, biochemical determinations on blood and urine, and electroencephalographic studies. We report herein the data on 48 children with AS who were enrolled in a double-blind placebo-controlled protocol using betaine and folic acid for 1 year. There were no statistically significant changes between treated and untreated children; however, in a small subset of patients we observed some positive trends.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1552-4833
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
152A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1994-2001
pubmed:dateRevised
2011-9-19
pubmed:meshHeading
pubmed-meshheading:20635355-Adolescent, pubmed-meshheading:20635355-Angelman Syndrome, pubmed-meshheading:20635355-Betaine, pubmed-meshheading:20635355-Child, pubmed-meshheading:20635355-Child, Preschool, pubmed-meshheading:20635355-Chromosomes, Human, Pair 15, pubmed-meshheading:20635355-DNA Methylation, pubmed-meshheading:20635355-Double-Blind Method, pubmed-meshheading:20635355-Drug Combinations, pubmed-meshheading:20635355-Female, pubmed-meshheading:20635355-Folic Acid, pubmed-meshheading:20635355-Genomic Imprinting, pubmed-meshheading:20635355-Humans, pubmed-meshheading:20635355-Infant, pubmed-meshheading:20635355-Lipotropic Agents, pubmed-meshheading:20635355-Male, pubmed-meshheading:20635355-Phenotype, pubmed-meshheading:20635355-Placebos, pubmed-meshheading:20635355-Ubiquitin-Protein Ligases, pubmed-meshheading:20635355-Vitamin B Complex
pubmed:year
2010
pubmed:articleTitle
Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid.
pubmed:affiliation
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't